Summarising a recent Daily Citizen article by Glenn T. Stanton titled: “The New York Times’ and 20 State AGs Expose Medical Groups’ Trans Agenda
A series of recent developments in the United States is highlighting the fragility of longstanding assertions about “gender-affirming care.” Legal rulings, institutional acknowledgements, and commentary from traditionally progressive outlets are exposing significant weaknesses in the medical community’s backing for transgender interventions in minors. These developments suggest an increasing awareness that the evidence supporting these practices has been exaggerated or, in some cases, inaccurately portrayed.
In late January, a New York jury awarded $2 million to Fox Varian, a young woman who underwent a double mastectomy at age 15 in an attempt to treat her gender dysphoria. The ruling suggests that US courts may finally be reconsidering the medical responsibility and informed‑consent standards surrounding such procedures.
Following this landmark case, two major medical organisations — the American Society of Plastic Surgeons and the American Medical Association — acknowledged that existing research does not provide enough evidence to support the removal of healthy organs from children and adolescents.
This represents a major shift from previous years’ insistent claims about the safety and effectiveness of these sex-rejecting interventions.
On Feb 23rd, 20 state attorneys general sent a letter to the AMA CEO, praising the AMA’s new opposition to surgery for gender-dysphoric minors but criticising its continued support for puberty blockers and cross-sex hormones.
Citing the 2024 Cass Review systematic review, they challenged the AMA’s claim of “settled science” on hormonal interventions. The 13-page letter (with 41 footnotes) includes 14 pointed questions about the AMA’s involvement in the Tennessee Skrmetti case, alignment with WPATH and AAP policies and its own literature reviews on efficacy.
Perhaps the most unexpected development is from The New York Times, which published an exposé by journalist Jesse Singal. Long known for his reporting on transgender medicine, Singal argues that prominent U.S. medical associations have subordinated science to gender and identity politics.
In his analysis, Singal writes that advocates, including leading medical bodies, have promoted a “naïve understanding” of what science can and cannot say — especially when evidence remains weak and of low-quality. He highlights how liberal organisations such as Gays and Lesbians Alliance Against Defamation and the American Civil Liberties Union have claimed unanimous expert support for gender‑affirming treatments while dismissing even mild scepticism as bigotry.
The op-ed indicates a significant shift in mainstream journalism in the US, with it now more willing to challenge pro-trans rhetoric, particularly from major medical professional bodies.
Both Singal and Stanton highlight how the American Academy of Paediatrics has shown a pattern of allowing ideological commitments to shape its recommendations. A notable example is a 2002 AAP technical report endorsing intentionally motherless or fatherless households as optimal environments for children — a position Stanton argues was more politically than scientifically motivated.
For over a decade, advocates claimed that “the science is settled.” However, these developments indicate otherwise and that the trans narrative’s media shield is cracking. Stanton cites that the combined weight of recent legal rulings, medical‑society admissions, and the NYT’s unexpected critique exposes a collapsing facade. In fact, the evidence highlights a long-standing trend: elite medical organisations adopting activist positions while claiming scientific neutrality.
Science is dismantling the myths, the trans agenda is being exposed, and the debate on these harmful sex-rejecting treatments is finally grounded in reality—not ideology.
